Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. 1996

U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
First Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan.

MCI-186 (3-methyl-1-phenyl-2-pyrazolin-5-one) is a newly developed antioxidant which has been shown to reduce brain edema in cerebral ischemia through inhibition of the lipoxygenase pathway of arachidonic acid. However, its effect on myocardial reperfusion injury after prolonged ischemia has not yet been demonstrated. We compared the mode of the effect of MIC-186 and recombinant human CuZn superoxide dismutase (rh-SOD) in isolated perfused rat hearts subjected to 60-min ischemia followed by 60-min reperfusion. Left ventricular developed pressure (LVDP), necrotic area and the release of creatine phosphokinase (CPK) and endogenous CuZn superoxide dismutase (endoge-SOD) were measured to evaluate myocardial damage. The decrease in left coronary flow (CBF) was measured as an index of the damage of left coronary circulation. MCI-186 (14.5 mg/L) was perfused for 10 min in the MCI group and rh-SOD (70 mg/L) was perfused during the reperfusion period in the SOD group starting 5 min prior to reperfusion. The release patterns of CPK and endoge-SOD were analyzed to elucidate the difference in the mode of protection of MCI-186 and rh-SOD. The LVDP remained higher in both MCI and SOD groups than that of control (76 +/- 1, 77 +/- 2 and 69 +/- 1% of preischemic value, respectively). The necrotic area was significantly attenuated in both MCI and SOD groups compared with that in the control group (16 +/- 1, 14 +/- 1 and 32 +/- 1%, respectively, p < 0.05). Total CPK release was lower in both MCI and SOD groups than in the control (78 +/- 7, 100 +/- 2 and 116 +/- 4 x 10(3) units/g myocardium respectively). The decrease in CPK release was more marked in the MCI group than that in the SOD group (p < 0.05). The reduction in CBF was significantly attenuated by the treatment with rh-SOD or MCI-186, but the effect was much higher in the SOD group than in the MCI group (69 +/- 5, 58 +/- 2, and 48 +/- 2% in SOD, MCI and control groups, respectively). The release pattern of endoge-SOD was identical to that of CPK and thus this did not distinguish the mode of effect of MCI-186 from that of rh-SOD. These results indicate that MCI-186 reduces reperfusion injury in isolated perfused hearts with prolonged ischemia and the effect is more closely related to the reduction of myocyte damage than the preservation of the coronary circulation.

UI MeSH Term Description Entries
D008297 Male Males
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077553 Edaravone An antipyrine derivative that functions as a free radical scavenger and neuroprotective agent. It is used in the treatment of AMYOTROPHIC LATERAL SCLEROSIS and STROKE. 1-Phenyl-3-methyl-5-pyrazolone,3-Methyl-1-phenyl-2-pyrazolin-5-one,Edarabone,MCI 186,MCI-186,Norantipyrine,Norphenazone,Phenylmethylpyrazolone,Radicava,1 Phenyl 3 methyl 5 pyrazolone,3 Methyl 1 phenyl 2 pyrazolin 5 one,MCI186
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
June 1996, Transplantation proceedings,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
November 2002, Transplantation,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
August 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
January 1989, Current surgery,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
August 2004, The Journal of surgical research,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
September 1990, The American journal of physiology,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
January 1991, Arkhiv patologii,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
April 1997, The Annals of thoracic surgery,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
October 1999, Archives of pharmacal research,
U Minhaz, and M Tanaka, and H Tsukamoto, and K Watanabe, and S Koide, and A Shohtsu, and H Nakazawa
April 1995, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
Copied contents to your clipboard!